総合安全衛生管理機構

林 愛子

AIKO HAYASHI

基本情報

所属
千葉大学  総合安全衛生管理機構 助教授
学位
医学博士(2019年3月 千葉大学)

J-GLOBAL ID
202201011012148456
researchmap会員ID
R000039738

論文

 12
  • Toshiki Namiki, Minoru Takemoto, Aiko Hayashi, Hiroki Yamagata, Takahiro Ishikawa, Koutaro Yokote, Shu-Yang Li, Masaaki Kubota, Bo-Shi Zhang, Yoichi Yoshida, Tomoo Matsutani, Seiichiro Mine, Toshio Machida, Yoshio Kobayashi, Jiro Terada, Akira Naito, Koichiro Tatsumi, Hirotaka Takizawa, Rika Nakamura, Hideyuki Kuroda, Yasuo Iwadate, Takaki Hiwasa
    BMC endocrine disorders 23(1) 239-239 2023年10月30日  
    BACKGROUND: Autoantibodies develop in autoimmune diseases, cancer, diabetes mellitus (DM), and atherosclerosis-related diseases. However, autoantibody biomarkers have not been successfully examined for diagnosis and therapy. METHODS: Serological identification of antigens through recombinant cDNA expression cloning (SEREX) was used for primary screening of antigens. The cDNA product was expressed in bacteria and purified. Amplified luminescent proximity homogeneous assay-linked immunosorbent assay (AlphaLISA) was used to evaluate antibody levels in serum samples. RESULTS: Phosphoenolpyruvate carboxykinase 1 (PCK1) was recognized as an antigen by serum IgG antibodies in the sera of patients with atherosclerosis. AlphaLISA showed significantly higher serum antibody levels against recombinant PCK1 protein in patients with DM and cardiovascular disease than in healthy donors, but not in those with acute ischemic stroke, transient ischemic attack, or obstructive sleep apnea syndrome. The area under the receiver operating characteristic curve for anti-PCK1 antibodies was 0.7024 for DM. The serum anti-PCK1 antibody levels were associated with age, platelet count, and blood pressure. Anti-PCK1-antibody-positive patients showed significantly lower overall survival than the negative patients. CONCLUSIONS: Serum anti-PCK1 antibody levels were found to be associated with DM. The anti-PCK1 antibody marker is useful for predicting the overall survival of patients with DM.
  • Daisuke Kinoshita, Hisaya Kato, Hiyori Kaneko, Takahiro Ishikawa, Naoya Teramoto, Ayano Tsukagoshi, Yukari Maeda, Takuya Minamizuka, Aiko Hayashi, Mayumi Shoji, Daisuke Sawada, Shinichiro Funayama, Masaya Koshizaka, Hideyuki Ogata, Yoshitaka Kubota, Nobuyuki Mitsukawa, Minoru Takemoto, Koutaro Yokote, Yoshiro Maezawa
    Geriatrics & gerontology international 23(3) 239-241 2023年2月1日  
  • Takuya Minamizuka, Masaya Koshizaka, Mayumi Shoji, Masaya Yamaga, Aiko Hayashi, Kana Ide, Shintaro Ide, Takumi Kitamoto, Kenichi Sakamoto, Akiko Hattori, Takahiro Ishikawa, Junji Kobayashi, Yoshiro Maezawa, Kazuki Kobayashi, Minoru Takemoto, Masaru Inagaki, Akira Endo, Koutaro Yokote
    Asia Pacific journal of clinical nutrition 30(3) 424-435 2021年9月  
    BACKGROUND AND OBJECTIVES: Red yeast rice contains monacolin K, an inhibitor of cholesterol synthesis, and gamma-aminobutyric acid, a neurotransmitter. The daily dose of red yeast rice and monacolin K in previous studies was relatively high; therefore, there were safety concerns. We aimed to examine the effects of low daily dose red yeast rice on arteriosclerosis in patients with mild dyslipidemia. METHODS AND STUDY DESIGN: Eighteen patients without known cardiovascular disease and unsatisfactory low-density lipoprotein cholesterol (3.96±0.19 mmol/L) controlled only by diet therapy were randomly allocated to receive low dose red yeast rice (200 mg/day) containing 2 mg monacolin K or diet therapy alone for 8 weeks. The primary outcome was the absolute change in low-density lipoprotein cholesterol. Secondary outcomes included total cholesterol, apolipoprotein B, and blood pressure. RESULTS: Low-density lipoprotein cholesterol decreased significantly in the red yeast rice group than in the diet therapy group (median [interquartile range]: control -0.20 [-0.62, 1.19] mmol/L vs. red yeast rice -0.96 [-1.05, -0.34] mmol/L, p=0.030). The red yeast rice group also exhibited significant decreases in total cholesterol, apolipoprotein B, and blood pressure. No severe treatment-related adverse effects on muscles, liver, or renal function were observed. CONCLUSIONS: We found that patients in the red yeast rice group exhibited significant reductions in lowdensity lipoprotein cholesterol, total cholesterol, apolipoprotein B, and blood pressure without any recognised adverse effect. This suggests that low daily dose red yeast rice could reduce cardiovascular risk in patients with dyslipidemia.
  • Kenichi Sakamoto, Yasuro Furuichi, Masashi Yamamoto, Megumi Takahashi, Yoshihiro Akimoto, Takahiro Ishikawa, Takahiko Shimizu, Masanori Fujimoto, Aki Takada-Watanabe, Aiko Hayashi, Yoshitaka Mita, Yasuko Manabe, Nobuharu L Fujii, Ryoichi Ishibashi, Yoshiro Maezawa, Christer Betsholtz, Koutaro Yokote, Minoru Takemoto
    EMBO reports 20(11) e47957 2019年11月5日  
    In this study, we identified a previously uncharacterized skeletal satellite cell-secreted protein, R3h domain containing-like (R3hdml). Expression of R3hdml increases during skeletal muscle development and differentiation in mice. Body weight and skeletal muscle mass of R3hdml knockout (KO) mice are lower compared to control mice. Expression levels of cell cycle-related markers, phosphorylation of Akt, and expression of insulin-like growth factor within the skeletal muscle are reduced in R3hdml KO mice compared to control mice. Expression of R3hdml increases during muscle regeneration in response to cardiotoxin (CTX)-induced muscle injury. Recovery of handgrip strength after CTX injection was significantly impaired in R3hdml KO mice, which is rescued by R3hdml. Our results indicate that R3hdml is required for skeletal muscle development, regeneration, and, in particular, satellite cell proliferation and differentiation.
  • 林 愛子, 前澤 善朗, 前田 祐香里, 石川 崇広, 越坂 理也, 北原 綾, 小野 啓, 林 秀樹, 横手 幸太郎
    糖尿病 62(Suppl.1) S-261 2019年4月  

MISC

 8

共同研究・競争的資金等の研究課題

 1